The HDL paradox: What does it mean and how to manage low serum HDL cholesterol level?

Kardiologia Polska

Volumn 72, Issue 8, 2014, Pages 681-686

  Cybulska, Barbara ^a   Kłosiewicz Latoszek, Longina ^a,b  

^a NATIONAL FOOD AND NUTRITION INSTITUTE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; COLLAGEN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MYELOPEROXIDASE; NICOTINIC ACID; NITRIC OXIDE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; SERUM AMYLOID A; THROMBIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; ANTILIPEMIC AGENT;

ANTIATHEROGENIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL SURFACE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CHOLESTEROL TRANSPORT; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFECT; ENDOTHELIUM; ENDOTHELIUM CELL; FIBRINOLYSIS; GENETIC DISORDER; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; IN VITRO STUDY; INFLAMMATORY DISEASE; INFUSION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTIMA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER CELL; LUPUS ERYTHEMATOSUS; MACROPHAGE; MONOCYTE; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SLEEP DISORDERED BREATHING; SYNTHESIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM; BLOOD; FEMALE; HEALTH BEHAVIOR; HYPERCHOLESTEROLEMIA; MALE; RISK FACTOR;

CHOLESTEROL, HDL; FEMALE; HEALTH BEHAVIOR; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; MALE; RISK FACTORS;

EID: 84906847013     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/KP.a2014.0110     Document Type: Review

References (42)

1. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 2009; 302: 1993-2000.
2. Boekholdt SM, Arsenault BJ, Hovingh GK et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients. A meta-analysis. Circulation, 2013; 128: 1504-1512.
3. Silbernagel G, Schöttker, Appelbaum S et al. High-density lipoprotein cholesterol, coronary artery disease and cardiovascular mortality. Eur Heart J, 2013; 34: 3563-3571.
4. Angeloni E, Paneni F, Landmesser U et al. Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. Eur Heart J, 2013; 34: 3557-3562.
5. Woestijne AP, van der Graaf Y, Liem AH et al. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular event in patients with vascular disease on intensive lipid-lowering medication. J Am Coll Cardiol, 2013; 62: 1834-1841.
6. Ridker PM, Genset J, Boekholdt SM et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet, 2010; 376: 333-339.
7. Genset J. High-density lipoprotein and residual cardiovascular risk. J Am Coll Cardiol, 2013; 62: 1842-1844.
8. Ray KK, Cannon CP, Cairns R et al. Prognostic utility of apo B/AI, total cholesterol/HDL, non-HDL cholesterol, or CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol, 2009; 29: 424-430.
9. Barter P, Gotto AM, La Rosa JC et al. For the Treating to New Targets Investigators. HDL cholesterol and cardiovascular events. N Engl J Med, 2007; 357: 1301-1310.
10. Acharjee S, Boden WE, Hartigan PM et al. Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients. A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggresive Drug Evaluation). J Am Coll Cardiol, 2013; 62: 1826-1833.
11. Boden WE, Probstfield JL, Anderson T et al. For the AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011; 365: 2255-2267.
12. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomised placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reason for stopping study treatment. Eur Heart J, 2013; 34: 1279-1291.
13. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med, 2007; 357: 2109-2122.
14. Schwartz GG, Olsson AG, Abr M et al. Effects of dalcetrapib in patients with recent acute coronary syndrome. N Engl J Med, 2012; 367: 2089-2099.
15. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomized trials. Lancet, 2010; 376: 1670-1681.
16. Zheng C, Aikawa M. High-density lipoproteins: from function to therapy. J Am Coll Cardiol, 2012; 60: 2380-2383.
17. Schofield JD, France M, Ammori B et al. High-density lipoprotein cholesterol raising - does it matter ? Curr Opin Cardiol, 2013; 28: 464-474.
18. Rosenson RS, Brewer HB, Ansell B et al. Translation of high-density lipoprotein function into clinical practice. Current prospects and future challanges. Circulation, 2013; 128: 1256-1267.
19. Perez-Mendoz O, Pacheco HG, Martinez-Sanchez C, Franco M. HDL cholesterol in coronary artery disease risk: function or structure? Clin Chim Acta, 2014; 429: 111-122.
20. Luscher TF, Landmesser U, Eckardstein A, Fogelman AM. High-density lipoprotein. Vascular protective effects, dysfunction and potential as therapeutic target. Circ Res, 2014; 114: 171-182.
21. Khera AV, Cuchel M, de la Llera-Moya M et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med, 2011; 364: 127-135.
22. Khera AV, Rader DJ. Cholesterol efflux capacity. Full steam ahead or a bump on the road. Arterioscler Thromb Vasc Biol, 2013; 33: 1449-1451.
23. Kingwell BA, Chapman MJ. Future of high-density lipoprotein infusion therapies. Potential for clinical management of vascular disease. Circulation, 2013; 128: 1112-1121.
24. Soran H, Hama S, Yadav R, Durrington PN. HDL functionality. Curr Opin Lipidol, 2012; 23: 353-366.
25. Serban C, Muntean D, Mikhailidis DP et al. Dysfunctional HDL: the journey from savior to slayer. Clin Lipidol, 2014; 9: 49-59.
26. Huang Y, Didonato JA, Levison BS et al. An abudant dysfunctional apolipoprotein A in human atheroma. Nat Med, 2014, 2014; 20: 193-203.
27. Brousseau ME, Diffenderfer MR, Millar JS et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein AI metabolism and fecal sterol excretion. Atheroscler Thromb Vasc Biol, 2005; 25: 1057-1064.
28. Davies MJ, Richardson PD, Woolf N et al. Risk of thrombosis in human atherosclerotic plaques : role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J, 1993; 69: 377-381.
29. Felton CV, Crook D, Davies MJ, Oliver MF. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol, 1997; 17: 1337-1346.
30. Hafiane A, Genset J. HDL, atherosclerosis and emerging therapies. Cholesterol, 2013; http://dol.org/10.1155/2013/891403.
31. Tardif JC, Gregoire J, L'Allier PL et al. Effect of rHDL on Ather-osclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc, 2007; 297:1675-1682.
32. Chenevard R, Harlimann P, Spieker L et al. Reconstituted HDL in acute coronary syndromes. Cardiovasc Therapeutics, 2012; 30: e51-e57.
33. Shaw JA, Bobik A, Murphy RD et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res, 2008; 103: 1084-1091.
34. Calabresi L, Sirtori CR, Paoletti R, Franceschini G. Recombinant apolipoprotein A-I Milano for the treatment of cardiovascular diseases. Curr Atheroscler Rep, 2006; 8: 163-167.
35. Sirtori CR, Calabresi L, Franceschini G. Recombinant apolipoproteins for the treatment of vascular diseases. Atherosclerosis, 1999; 142: 29-40.
36. Chiesa G, Sirtori CR. Use of recombinant apolipoproteins in vascular diseases: the case of apo A-I. Curr Opin Investig Drugs, 2002; 3: 420-426.
37. Calabresi L, Canavesi M, Bernini F, Franceschini G. Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-I Milano dimer. Biochemistry, 1999; 38: 1607-16314.
38. Favari E, Gomaraschi M, Zanotti I et al. A unique protease-sensitive high density lipoprotein particle containing the the apolipoprotein A-I (Milano) dimer effectively promates ATP-binding Cassette A-I mediated cell cholesterol efflux. J Biol Chem, 2007; 282: 5126-5132.
39. Nissen SE, Tsunoda Y, Tuzcu EM et al. Effect of recombinant Apo A-I Milano on coronary syndromes : a randomized controlled trial. JAMA, 2003; 290: 2292-2300.
40. Toth PP, Barter PJ, Rosenson RS. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol, 2013; 7: 484-525.
41. Rynkiewicz A, Cybulska B, Banach M et al. Postȩpowanie w heterozygotycznej hipercholesterolemii rodzinnej. Stanowisko Forum Ekspertów Lipidowych. Kardiol Pol, 2013; 71: 102-111.
42. Cybulska B, Kłosiewicz-Latoszek L. Management of severe hypertriglyceridaemia. Kardiol Pol, 2013; 71: 1007-1012.